Suggested Dosing
Isoflavones
40 mg PO qD
Menopausal symptoms: 34-120 mg/d
Hypertension: 18 mg PO BID
Lung cancer prevention: 8.3 -83.2 mcg/d
Ipriflavone
200 mg PO TID
CrCl 40-80 mL/min
200 mg PO BID
CrCl <40 mL/min
200 mg PO qD
Suggested Uses
Menopausal vasomotor symptoms, osteoporosis
Decrease risk of breast cancer, CVD
Efficacy
Studies show reasonable efficacy for breast cancer, diabetes, osteoporosis prevention/treatment, hot flashes, CVD risk
Mixed results for cancer prevention
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
Frequency Not Defined
Allergic reaction
Warnings
Contraindications
Pregnancy
Pregnancy & Lactation
Pregnancy Category: avoid use
Lactation: N/A
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Metabolism: N/A
Excretion: N/A
Mechanism of Action
Partial estrogen receptor agonists; anti-estrogenic effects in premenopausal women, but weak estrogenic effects in postmenopausal women
May stimulate osteoblastic activity
Incr sex hormone binding globulin (SHBG) levels; antioxidant activity
